Viagra and shingles vaccine show surprising promise against Alzheimer’s

An international Delphi panel reviewed 80 approved drugs and identified three priority candidates for Alzheimer’s repurposing—Zostavax (shingles vaccine), sildenafil (Viagra), and riluzole—based on preclinical evidence and safety in older adults; prior observational data suggested shingles vaccination was associated with an ~16% lower dementia risk. The study, published in Alzheimer’s Research and Therapy and supported by Alzheimer’s Society and NIHR, calls for robust clinical trials (including a planned large UK trial using the PROTECT registry), a development that could alter prospects for vaccine and drug makers but remains conditional on trial outcomes.

Analysis

Market structure: Repurposing signals a modest structural tilt from high-risk, high-capex Alzheimer R&D toward low-cost, high-reach interventions (vaccines, generic drugs, CRO services). Winners are large integrated pharma with vaccine franchises and scale manufacturing (consolidated pricing power); losers are small-cap, indication-specific Alzheimer developers whose valuations assume proprietary, high-priced biologics. Expect incremental demand for CRO capacity and adult-vaccine cold-chain logistics; pricing pressure on future monoclonal antibody launches if a cheap preventive reduces addressable market by >10–20% over 2–5 years.

Risk assessment: Tail risks include negative RCTs, regulatory rejection of off-label prevention, supply constraints (Zostavax production retired in some markets) and patent/label/legal challenges — each could wipe 30–60% of the trade thesis value. Near-term (0–3 months) impact is negligible; medium (3–12 months) hinges on trial starts/interim readouts; long-term (2–5 years) depends on replication in Phase III and reimbursement decisions. Hidden dependencies: insurer uptake, primary-care adoption rates, and interaction with existing zoster vaccine replacement (Shingrix) materially change addressable market.

Trade implications: Favor defensive, cash-generative vaccine makers and CROs over speculative Alzheimer biotechs. Use relative-value to go long large-cap pharma and CRO services while hedging or shorting small-cap AD plays/biotech ETFs; options to express asymmetric upside on large caps with limited downside. Key catalysts: PROTECT registry trial launches, published observational cohort updates (look for ≥10–16% risk reduction signals), regulator statements within 6–12 months.

Contrarian angles: Consensus overlooks that Zostavax is an older live vaccine with limited use vs Shingrix — true commercial upside likely concentrated in GSK/Pfizer-like adjuvanted vaccines rather than Merck’s legacy brand. The market may be underpricing CRO upside and overpricing the threat to big-cap AD franchises. Historical parallel: aspirin’s repurposing produced persistent but modest population-level impact; expect a protracted, binary outcome where one robust RCT (or lack of it) drives multi-year flows.

Key Decisions for Investors

• Establish a 2–3% portfolio long split: MRK (Merck) 1.2% and GSK (GSK) 0.8%, size to 2–3% because vaccine trial activity and potential preventive indication catalyze revenue diversification over 12–24 months; add incremental 1% if PROTECT-linked trial launches within 90 days.
• Add 1–2% long in IQV (IQV) to capture outsourced trial volume; target 12-month horizon and expect revenues to rise 5–15% if multiple repurposing trials commence — trim if quarterly guidance misses by >5%.
• Implement a pair trade: long XLV (2%) vs short IBB (2%) to favor large-cap pharma/CRO exposure over small-cap biotech risk; rebalance if XLV/IBB spread narrows >200 bps or after any major Phase II/III negative readout.
• Buy 9-month call spread on MRK sized to 0.5–1% portfolio risk: buy 15% OTM call / sell 35% OTM call to capture asymmetric upside from positive interim vaccine-repurposing data while capping premium outlay; unwind if implied vol rises >30% without news.
• Contingency triggers (explicit): increase aggregate vaccine/CRO longs by +50% allocation if an RCT/interim analysis reports ≥10% reduction in dementia incidence with p<0.05 within 12 months; cut all exposure by 50% if observational meta-analyses/registries refute benefit or regulators issue negative guidance.